What Dydrogesterone Treats: Main Uses and Benefits

The medication is applied to address clinical situations stemming from progesterone deficiency. This progestogen is generally relevant where a lack of natural progesterone affects the stability of the uterine lining and contributes to gynecological symptoms.

Its primary uses cover scenarios where additional symptomatic support is needed, including early pregnancy support (for threatened or recurrent miscarriage), luteal phase support in assisted reproductive technology (ART), management of menstrual cycles (for absent or dysfunctional bleeding), easing of severe cyclical pain (for dysmenorrhea and endometriosis), and support of the uterine lining in Hormone Replacement Therapy (HRT). This treatment is designed to assist with managing symptoms that create noticeable physiological strain and interfere with daily comfort. The overall therapeutic goal is to help patients cope more steadily with symptom fluctuations and maintain a sense of stability.

Quick Fact: Support for Cyclical Discomfort
Symptom Domain	Benefit
Severe menstrual pain (Dysmenorrhea) and Endometriosis-related discomfort.	Contributes to easing the overall symptom load during symptomatic periods.
Clinical Context	Common Scenario
Conditions involving episodic or fluctuating manifestations.	Used during phases of increased distress or discomfort.

Regulatory References

1. Irish Health Products Regulatory Authority (HPRA) documentation

Official Eligibility and Non-Eligibility for Dydrogesterone

The eligibility criteria for dydrogesterone are strictly defined by regulatory authorities and based on patient population, medical history, and concurrent conditions. The drug is primarily for women of reproductive age and postmenopausal women (when used in Hormone Replacement Therapy (HRT) with oestrogen).

Absolute Contraindications
Known hypersensitivity to dydrogesterone or excipients.
Undiagnosed vaginal bleeding where the cause has not been established.
Known or suspected sex hormone-dependent malignancies (e.g., meningioma).
Presence of severe active liver disease or history until liver function values have normalized.

Age and Condition Restrictions

The medicine is not established for use in adolescents aged 12 to 18 years, and there is no relevant use established before menarche. Experience in treating women over 65 years is limited.

Use is not recommended while breastfeeding as a risk to the infant cannot be excluded. Though the drug may be administered during pregnancy for specific indications (e.g., threatened miscarriage) as no evidence of harmful effect has been found, it must be discontinued upon diagnosis of abortion or miscarriage during Assisted Reproductive Technology (ART) support. Additionally, conditions such as Porphyria or a history of depression require careful supervision.

Interactions with other medicines and products

Interactions with dydrogesterone are primarily related to its metabolism and specific co-administration rules documented in official labeling.

Pharmacokinetic Interactions (Increased Metabolism)

The co-administration of dydrogesterone with substances that are strong inducers of the CYP3A4 enzyme is officially documented to accelerate the metabolism of the progestogen. This increased metabolism can lead to a reduction in the effect of dydrogesterone and may result in changes to the patient's bleeding pattern. The reduction in exposure is a formal regulatory caution.

Substance Category	Examples of Listed Interacting Medicines
Anticonvulsants	Phenytoin, Phenobarbital, Carbamazepine
Anti-infectives	Rifampicin, Rifabutin, Nevirapine, Efavirenz

Herbal Products and Combination Restrictions

Official labeling notes that certain herbal preparations known to induce CYP isoenzymes, such as St. John’s Wort (Hypericum perforatum), can similarly increase dydrogesterone’s metabolism. Additionally, when dydrogesterone is used in combined Hormone Replacement Therapy (HRT) with an estrogen, the contraindications, warnings, and precautions associated with the estrogen component must be formally applied to the combination.

Agonism of Progesterone Receptors

Duphaston (dydrogesterone) is a synthetic progestogen that acts as a highly selective agonist for the progesterone receptor (PR). It initiates a signaling sequence by binding to and activating the PRs within target tissues, particularly the uterus, thereby modulating hormone-dependent processes.

---

Endometrial Transformation and Regulation

The compound's activity on the progesterone receptor modulates the key pathway associated with endometrial function. This involves suppressing the proliferative effects of estrogen and initiating the secretory phase morphology of the endometrium. This mechanism results in predictable structural and cellular changes within the targeted endometrium.

---

Immunological and Anti-Estrogenic Effects

Dydrogesterone engages mechanisms that influence feedback regulation within hormonal and cellular pathways, resulting in the inhibition of estrogen-mediated cellular responses in specific tissues. Furthermore, the compound and its primary active metabolite modulate local molecular mediators that are implicated in immune processes within targeted biological systems.

How to Use Duphaston (Dydrogesterone)

Duphaston (Dydrogesterone) is administered via the oral route as a 10 mg film-coated tablet, a standard instruction. The tablets are intended to be swallowed with water, and the score line on the tablet is present for ease of swallowing, not to permit division into equal halves.

Administration follows a regimen specific to the condition being addressed, often involving either cyclical use (e.g., specific days of a menstrual cycle) or a continuous daily schedule for certain hormonal support plans. Daily doses typically range from 10 mg to 30 mg, although acute, starting doses of up to 40 mg have been documented. When the total daily dose exceeds 10 mg, the official guideline is to administer the amount in divided doses spread evenly throughout the day.

Administration and Timing Rules

Feature	Official Usage Guideline
Route & Form	Oral intake of a 10 mg film-coated tablet.
Dosing Frequency	Daily doses above 10 mg must be taken in divided doses.
Missed Dose	If a dose is forgotten and more than 12 hours have elapsed, that tablet should be skipped, and the standard schedule should be continued with the next dose.
Treatment Duration	Use for long-term support (e.g., prevention of habitual patterns) often continues until a defined point in time (e.g., 20 weeks of pregnancy) and is then gradually tapered off.

Use is not established in adolescents before menarche due to a lack of safety and efficacy data. The established instructions define a standardized protocol governing the amount, frequency, and duration for using the medicine.

Research Evidence / Overview of Studies for Duphaston

Evidence for Use in Assisted Reproductive Technology (ART)

Research was studied for luteal phase support in women undergoing procedures like In Vitro Fertilization (IVF) and embryo transfer. Studies explored the use of dydrogesterone alongside the concurrent standard of care. Research monitored measurements related to initial uterine changes and the progression of pregnancy outcomes. The primary measurements tracked include the Live Birth Rate (LBR)—the number of live deliveries—and the Ongoing Pregnancy Rate.

Data show patterns related to measured LBR and Ongoing Pregnancy Rate in populations studied. Data are still emerging related to the overall impact of dydrogesterone on endometrial biomarkers in the ART setting. Long-term effects related to developmental milestones of children exposed in utero are not fully established.

Evidence for Early Pregnancy Support

Clinical evidence primarily focuses on Threatened Miscarriage and Recurrent Miscarriage. These areas was evaluated in Randomized Controlled Trials and subsequent Meta-analyses. Research examined whether dydrogesterone was associated with a change in the Miscarriage Rate and how that related to the Live Birth Rate (LBR). In women with a history of recurrent miscarriage, studies reported measurements of miscarriage rates, though the findings were mixed across different studies, especially those focusing on threatened miscarriage.

Evidence quality varies across studies, sometimes due to factors like study design or small sample size, which can lead to uncertainty. Follow-up durations were limited in some trials, focusing primarily on outcomes up to the time of delivery.

Evidence for Managing Gynecological Pain and Irregular Cycles

Research has explored the use of dydrogesterone in research scenarios involving fluctuating or episodic manifestations, such as pain related to Endometriosis and Severe Menstrual Pain (Dysmenorrhea). Studies monitored changes in outcomes related to physical discomfort (pain scores) and frequency of analgesic use. Post-marketing data show patterns related to high measurements of cycle regularity achieved over several treatment cycles for irregular menstrual cycles.

For pain conditions, the evidence is limited by the fact that many studies are short-term. Comparative evidence is lacking for certain indications, meaning that dydrogesterone has not always been directly compared to a true placebo in every single study scenario. Researchers continue to explore different patterns of use, confirming that certainty remains low in these areas.

Common questions about Дуфастон (FAQ)

Q: What is Дуфастон used for?

Дуфастон (Dydrogesterone) is a medication that contains a form of the hormone progesterone. It is primarily used to treat conditions caused by a lack of this natural hormone in the body.

It can be prescribed for:

• Treating endometriosis (where tissue similar to the lining of the womb grows elsewhere in the body).
• Managing symptoms of painful or irregular periods.
• Treating certain types of infertility associated with low progesterone levels.
• Supporting the lining of the womb (endometrium) as part of Hormone Replacement Therapy (HRT) in women who still have a uterus.
• Preventing threatened or habitual miscarriage in cases where the cause is determined to be progesterone deficiency.

---

Q: How does Дуфастон work?

Дуфастон contains the active ingredient dydrogesterone, which is a synthetic substance chemically very similar to the natural hormone progesterone.

Dydrogesterone works by mimicking the effects of natural progesterone in the body. Its primary action is on the endometrium (the lining of the uterus).

• In menstrual disorders and HRT, it helps regulate the growth and shedding of the endometrium.
• In cases of progesterone deficiency, it replaces the missing hormone to help maintain the uterine lining, which is essential for a successful pregnancy.

It is often described as an oral progestogen that is well-tolerated and acts selectively on the uterus.

---

Q: What are the common side effects of Дуфастон?

As with any medicine, Дуфастон can cause side effects, although not everyone gets them.

Common side effects (may affect up to 1 in 10 people) include:

• Headache
• Nausea (feeling sick)
• Abdominal pain
• Menstrual disorders, such as heavier bleeding (menorrhagia), less bleeding (oligomenorrhea), or no bleeding (amenorrhea), and irregular periods.
• Breast pain or tenderness

Less common side effects (may affect up to 1 in 100 people) include:

• Weight gain
• Dizziness
• Vomiting (being sick)
• Allergic skin reactions, such as rash or itching

If you experience any severe or persistent side effects, or notice signs of a serious allergic reaction, you should seek medical attention immediately.

---

Q: Can Дуфастон be used during pregnancy?

Yes, Дуфастон may be used during pregnancy, but only under specific medical guidance.

It is sometimes prescribed in the first trimester (first 12 weeks) to help prevent threatened miscarriage or habitual miscarriage (recurrent pregnancy loss) in women where the cause is identified as progesterone deficiency.

It is not recommended for use to prevent miscarriage in women where the cause is unknown or due to other factors.

If prescribed, its use is carefully monitored by a doctor, who will weigh the potential benefits against any risks. You should always discuss the use of any medication during pregnancy with your healthcare provider.

---

Q: What should I do if I forget to take a dose of Дуфастон?

If you forget to take a dose, what you should do depends on how much time has passed since the missed dose:

• If it has been less than 12 hours since the missed dose, take the missed dose as soon as you remember.
• If it has been more than 12 hours since the missed dose, simply skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the forgotten one.

Missing a dose, especially if it's part of a cycle, may lead to breakthrough bleeding or spotting. Always follow the specific instructions and advice given by your prescribing doctor.

How to Store Duphaston (Dydrogesterone)

Official regulatory documents define strict storage conditions to maintain the stability of Duphaston tablets. The medicine must be stored at a temperature not exceeding 30 C and must not be frozen [Source: Official government labeling].

To ensure product integrity, the tablets must be kept in their original packaging and stored in a dry place, protected from light [Source: Official government labeling]. The labeled shelf life of the product is 5 years when stored correctly.

Child Safety and Disposal Requirements

It is mandatory to keep this medicine out of the sight and reach of children [Source: Official government labeling].

For disposal, unused or expired Duphaston tablets must not be thrown into household waste or wastewater [Source: Official government labeling]. Regulatory instructions require that the product be returned to a pharmacist or healthcare professional for proper pharmaceutical waste handling.